3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
Abstract
This invention relates to the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for higher order behaviors. These brain networks are involved in cognitive abilities related to memory impairment, such as is observed in a variety of dementias, an in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia and affective disorders. In a particular aspect, the present invention relates to a compound useful for treatment of such conditions, and methods of using this compound for such treatment.
Claims
exact text as granted — not AI-modified1. A compound of the formula:
or a pharmaceutically acceptable addition salt of an acid or base thereof.
2. A method for treating a condition selected from schizophrenia, Parkinson's disease, and Alzheimer's disease in a subject in need thereof, said method comprising administering to said subject, in a pharmaceutically acceptable carrier, an effective amount of a compound according to claim 1 .
3. The method according to claim 2 wherein said condition is schizophrenia.
4. The method according to claim 2 wherein said condition is Parkinson's disease.
5. The method according to claim 2 wherein said condition is Alzheimer's disease.
6. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 in combination with a pharmaceutically acceptable carrier, additive or excipient.
7. The composition according to claim 6 wherein said compound comprises about 0.5% to about 75% by weight of said composition and said carrier, additive or excipient comprises about 25% to about 95.5% of said composition.Join the waitlist — get patent alerts
Track US8173644B2 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.